In glioma mice, combined therapy of anti-CXCR4 and anti-PD-1 reduced immunosuppressive leukocytes counts, advanced the CD4+/CD8+ T cell ratio and raised the amount of pro-inflammatory cytokines (91). This evidence concerns the gene CXCR4 and central nervous system cancer.